Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)
Copenhagen, Denmark, 21 December 2021 - Curasight A/S (“Curasight” or the “Company”) appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company.“We are most pleased to have Hanne joining the team at Curasight. With her impressive track-record and in-depth knowledge in drug